Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 55-SOCRATE
2024-513515-27-00Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab monotherapy with Ramucirumab plus paclitaxel (2 arms). Primary endpoint: Six-month survival rate and quality of life at 4 months. Started Jul 2024; status: completed.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-513515-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513515-27-00.